REGULATORY

• Shiozaki Does Not Rule Out Price Cut of Over 25% for Opdivo
  October 27, 2016

• MHLW Alerts on Risk of Fulminant Type 1 Diabetes for Keytruda
  October 25, 2016

• Pharma Groups Tender Requests to LDP on FY2017 Budget, Tax Reform
  October 24, 2016

• Govt Panel Members Call for Drastic Drug Pricing Reform, Annual Revision
  October 24, 2016

• Keytruda’s November Listing Skip Likely amid Opdivo Re-Pricing Fuss
  October 24, 2016

• New Govt Panel Holds 1st Meeting for Healthcare, Long-Term Care
  October 21, 2016

• MHLW Panel to Discuss Health Coverage of Ethical Drugs with OTC Versions on Oct. 26
  October 21, 2016

• Oct. 27 MHLW Panel Meeting Postponed Due to Lack of Quorum
  October 21, 2016

• Basic Policy on JP 18th Edition Calls for Expansion of Sections Related to Biopharmaceuticals: MHLW
  October 21, 2016

• Heads of Medicines Regulatory Agencies to Hold Summit in Kyoto Next October
  October 20, 2016

• Shiozaki Asks for Early Enactment of Clinical Research Bill
  October 20, 2016

• MHLW Task Force Calls for Consolidation in Vaccines, Blood Products Industries; “Fundamental to National Security”: Minister
  October 20, 2016

• LDP Taskforce Agrees to Squeeze Social Security Budget by 140 Billion Yen
  October 19, 2016

• Opdivo Ordered to Add Immune Thrombocytopenic Purpura in ADR List
  October 19, 2016

• Concomitant Use of Warfarin and Florid Contraindicated: MHLW
  October 19, 2016

• Health Minister Nudges Kaketsuken on Biz Handover to Astellas
  October 19, 2016

• Urgent Need for Rule on Interim NHI Price Revisions; Current System Unable to Respond in Case of Add’l Indications: MOF Budget Examiner
  October 19, 2016

• MHLW Panel to Review Ono’s Etelcalcetide on Oct. 31
  October 18, 2016

• Govt to Stockpile Qinghai Strain Pre-Pandemic Flu Vaccines
  October 18, 2016

• Govt Panel Member Pushes 50%-Plus Cut for Opdivo Price
  October 17, 2016

ページ

• « 先頭
• ‹ Prev
• …
• 262
• 263
• 264
• 265
• 266
• 267
• 268
• 269
• 270
• …
• Next ›
• 最終 »